Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 1/2014

01-03-2014 | Epidemiology and Pathophysiology (PR Ebeling and EF Eriksen, Section Editors)

Review: Epidemiology and Pathophysiology of Atypical Femur Fractures

Authors: Alvin C. Ng, Meng Ai Png, David T. Chua, Joyce S. B. Koh, Tet Sen Howe

Published in: Current Osteoporosis Reports | Issue 1/2014

Login to get access

Abstract

The recent recognition of the clinical phenomenon of atypical femoral fractures has garnered significant scientific interest. In this review, we will discuss and summarize the salient developments in the current understanding of the epidemiology, pathophysiology, and radiology of atypical femoral fractures.
Literature
1.
Nieves JW, Cosman F. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep. 2010;8:34–9.PubMedCrossRef
2.••
Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25:2267–94. This is the seminal report from the task force commissioned by the American Society of Bone and Mineral Research, which proposed the original case definition and summarized the collective experience and published data on AFFs.
3.
Kumm DA, Rack C, Rutt J. Subtrochanteric stress fracture of the femur following total knee arthroplasty. J Arthroplasty. 1997;12:580–3.PubMedCrossRef
4.
Husada G, Libberecht K, Peeters T, Populaire J. Bilateral mid-diaphyseal femoral stress fractures in the elderly. Eur J Trauma. 2005;31:68–71.CrossRef
5.
Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res. 2009;24:1736–40.PubMedCrossRef
6.
Odvina CV, Levy S, Rao S, Zerwekh JE, Sudhaker Rao D. Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol. 2010;72:161–8.CrossRef
7.
Sayed-Noor AS, Sjoden GO. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res. 2009;467:1921–6.PubMedCrossRef
8.
Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–301.PubMedCrossRef
9.
Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89:349–53.PubMedCrossRef
10.
Salminen S, Pihlajamaki H, Avikainen V, Kyro A, Bostman O. Specific features associated with femoral shaft fractures caused by low-energy trauma. J Trauma. 1997;43:117–22.PubMedCrossRef
11.
Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346–50.PubMedCrossRef
12.
Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf. 2009;32:775–85.PubMedCrossRef
13.
Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008;93:2948–52.PubMedCrossRef
14.
Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg. 2009;91:2556–61.PubMedCrossRef
15.
Demiralp B, Ilgan S, Ozgur Karacalioglu A, Cicek EI, Yildrim D, Erler K. Bilateral femoral insuffiency fractures treated with inflatable intramedullary nails: a case report. Arch Orthop Trauma Surg. 2007;127:597–601.PubMedCrossRef
16.
Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39:224–31.PubMedCrossRef
17.
Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics. 2006;61:31–3.PubMed
18.
Lee P, van der Wall H, Seibel MJ. Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with postmenopausal osteoporosis on alendronate therapy. J Endocrinol Investig. 2007;30:590–7.
19.
Cheung RK, Leung KK, Lee KC, Chow TC. Sequential nontraumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J. 2007;13:485–9.PubMed
20.
21.
Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab. 2010;95:5258–65.PubMedCrossRef
22.
Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009;24:1095–102.PubMedCrossRef
23.
Hsiao FY, Huang WF, Chen YM, Wen YW, Kao YH, Chen LK, et al. Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women. Clin Ther. 2011;33:1659–67.PubMedCrossRef
24.
Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res. 2011;26:993–1001.PubMedCrossRef
25.
Nieves JW, Bilezikian JP, Lane JM, Einhorn TA, Wang Y, Steinbuch M, et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int. 2010;21:399–408.PubMedCrossRef
26.
Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res. 2011;26:553–60.PubMedCrossRef
27.
Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009;20:1353–62.PubMedCrossRef
28.
Girgis CM, Sher D, Seibel MJ. Atypical femoral fractures and bisphosphonate use. N Engl J Med. 2010;362:1848–9.PubMedCrossRef
29.
Giusti A, Hamdy NA, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone. 2011;48:966–71.PubMedCrossRef
30.
Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364:1728–37.PubMedCrossRef
31.
Thompson RN, Phillips JR, McCauley SH, Elliott JR, Moran CG. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J Bone Joint Surg Br. 2012;94:385–90.PubMedCrossRef
32.
Feldstein AC, Black D, Perrin N, Rosales AG, Friess D, Boardman D, et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res. 2012;27:977–86.PubMedCrossRef
33.
Lo JC, Huang SY, Lee GA, Khandelwal S, Provus J, Ettinger B, et al. Clinical correlates of atypical femoral fracture. Bone. 2012;51:181–4.PubMedCrossRef
34.
Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012;27:2544–50.PubMedCrossRef
35.
Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Int Med. 2012;172:930–6.
36.
Warren C, Gilchrist N, Coates M, Frampton C, Helmore J, McKie J, et al. Atypical subtrochanteric fractures, bisphosphonates, blinded radiological review. ANZ J Surg. 2012;82:908–12.PubMedCrossRef
37.
Shkolnikova J, Flynn J, Choong P. Burden of bisphosphonate-associated femoral fractures. ANZ J Surg. 2013;83:175–81.PubMedCrossRef
38.
Allen MR, Gineyts E, Leeming DJ, Burr DB, Delmas PD. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int. 2008;19:329–37.PubMedCrossRef
39.
Tang SY, Zeenath U, Vashishth D. Effects of nonenzymatic glycation on cancellous bone fragility. Bone. 2007;40:1144–51.PubMedCrossRef
40.
Donnelly E, Meredith DS, Nguyen JT, Gladnick BP, Rebolledo BJ, Shaffer AD, et al. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res. 2012;27:672–8.PubMedCrossRef
41.
Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int. 2001;69:281–6.PubMedCrossRef
42.
Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone. 2007;41:378–85.PubMedCrossRef
43.
Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N, et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res. 2007;22:1502–9.PubMedCrossRef
44.
Li J, Miller MA, Hutchins GD, Burr DB. Imaging bone microdamage in vivo with positron emission tomography. Bone. 2005;37:819–24.PubMedCrossRef
45.
Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302:1055–61.PubMedCrossRef
46.
Howe TS, Erlich G, Koh JS, Ng AC, Costerton W. A case of an atypical femoral fracture associated with bacterial biofilm—pathogen or bystander? Osteoporos Int. 2013;24:1765–6.PubMedCrossRef
47.
48.
Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997;100:1475–80.PubMedCentralPubMedCrossRef
49.
Eriksen EF, Melsen F, Sod E, Barton I, Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone. 2002;31:620–5.PubMedCrossRef
50.
Whyte MP, Bergfeld MA, Murphy WA, Avioli LV, Teitelbaum SL. Postmenopausal osteoporosis. A heterogeneous disorder as assessed by histomorphometric analysis of iliac crest bone from untreated patients. Am J Med. 1982;72:193–202.PubMedCrossRef
51.
Hauge E, Mosekilde L, Melsen F. Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach. Bone. 1999;25:389–95.PubMedCrossRef
52.
Tan SC, Koh SB, Goh SK, Howe TS. Atypical femoral stress fractures in bisphosphonate-free patients. Osteoporos Int. 2011;22:2211–2.PubMedCrossRef
53.
Whyte MP. Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. J Bone Miner Res. 2009;24:1132–4.PubMedCrossRef
54.
Schilcher J, Koeppen V, Ranstam J, Skripitz R, Michaelsson K, Aspenberg P. Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone. 2013;52:389–92.PubMedCrossRef
55.
Mohan PC, Howe TS, Koh JS, Png MA. Radiographic features of multifocal endosteal thickening of the femur in patients on long-term bisphosphonate therapy. Eur Radiol. 2013;23:222–7.PubMedCrossRef
56.
Koeppen VA, Schilcher J, Aspenberg P. Atypical fractures do not have a thicker cortex. Osteoporos Int. 2012;23:2893–6.PubMedCrossRef
57.••
Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2014. This is the second report from the ASBMR Task Force, which proposes revisions to the case definition of AFFs, as well as provides comprehensive updates in the area of epidemiology and risk factors, pathogenesis, and medical management.
58.
Ng AC, Png MA, Mohan PC, Koh JS, Howe TS. Atypical femoral fractures—transverse morphology at lateral cortex is a critical feature. J Bone Miner Res. 2013.
59.
Ha YC, Cho MR, Park KH, Kim SY, Koo KH. Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res. 2010;468:3393–8.PubMedCrossRef
60.
Allison MB, Markman L, Rosenberg Z, Vieira RL, Babb J, Tejwani N, et al. Atypical incomplete femoral fractures in asymptomatic patients on long term bisphosphonate therapy. Bone. 2013;55:113–8.PubMedCrossRef
61.
Koh JS, Goh SK, Png MA, Ng AC, Howe TS. Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology. Singap Med J. 2011;52:77–80.
62.
Png MA, Koh JS, Goh SK, Fook-Chong S, Howe TS. Bisphosphonate-related femoral periosteal stress reactions: scoring system based on radiographic and MRI findings. Am J Roentgenol. 2012;198:869–77.CrossRef
63.
Saleh A, Hegde VV, Potty AG, Schneider R, Cornell CN, Lane JM. Management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures. HSS J. 2012;8:103–10.PubMedCentralPubMedCrossRef
64.
Koh JS, Goh SK, Png MA, Kwek EB, Howe TS. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma. 2010;24:75–81.PubMedCrossRef
65.
Chan SS, Rosenberg ZS, Chan K, Capeci C. Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. Am J Roentgenol. 2010;194:1581–6.CrossRef
66.
de Limaa JG, da Costa Fernandesa F, de Souzaa AB, dos Santos Juniora AC, Reboucasa BM, de Limaa NN, et al. Atypical fracture with use of ibandronate and the role of bone scintigraphy on its early diagnosis. J Endocrinol Metabol. 2013;3:67–9.
67.
Crossley K, Bennell KL, Wrigley T, Oakes BW. Ground reaction forces, bone characteristics, and tibial stress fracture in male runners. Med Sci Sports Exerc. 1999;31:1088–93.PubMedCrossRef
68.
Oh Y, Wakabayashi Y, Kurosa Y, Ishizuki M, Okawa A. A stress fractures of bowing femoral shaft in the elderly—another cause of atypical femoral fractures. Bone Joint J Orthopaed Proc. 2013;(Suppl 95-B):9.
69.
Ikeda S, Sakai A, Tanaka H, Takeuchi Y, Ohnishi H, Murakami H, et al. Atypical femoral fractures were associated with deterioration of bone quality and curvature of femoral shaft. Bone Joint J Orthopaed Proc. 2013;(Suppl 95-B):67.
70.
Ettinger B, Burr DB, Ritchie RO. Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone. 2013;55:495–500.PubMedCrossRef
71.
Karakas HM, Harma A. Femoral shaft bowing with age: a digital radiological study of Anatolian Caucasian adults. Diagn Interv Radiol. 2008;14:29–32.PubMed
72.
73.
74.
Nakamura T, Turner CH, Yoshikawa T, Slemenda CW, Peacock M, Burr DB, et al. Do variations in hip geometry explain differences in hip fracture risk between Japanese and White Americans? J Bone Miner Res. 1994;9:1071–6.PubMedCrossRef
75.
Brownbill RA, Ilich JZ. Hip geometry and its role in fracture: what do we know so far? Curr Osteoporos Rep. 2003;1:25–31.PubMedCrossRef
76.
Novotny R, Daida YG, Grove JS, Le Marchand L, Vijayadeva V. Asian adolescents have a higher trunk: peripheral fat ratio than Whites. J Nutr. 2006;136:642–7.PubMedCentralPubMed
77.
Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362:1761–71.PubMedCrossRef
78.
Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–38.PubMedCrossRef
79.
Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial; FIT Research Group. J Clin Endocrinol Metab. 2000;85:4118–24.PubMedCrossRef
80.
Mashiba T, Turner CH, Hirano T, Forwood MR, Jacob DS, Johnston CC, et al. Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. Bone. 2001;29:271–8.PubMedCrossRef
81.
Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479–91.PubMedCrossRef
82.
Schneider JP, Hinshaw WB, Su C, Solow P. Atypical femur fractures: 81 individual personal histories. J Clin Endocrinol Metab. 2012;97:4324–8.PubMedCrossRef
83.
Imai K, Yamamoto S, Anamizu Y, Horiuchi T. Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metabol. 2007;25:333–6.CrossRef
84.
Ang BF, Koh JS, Ng AC, Howe TS. Bilateral ulna fractures associated with bisphosphonate therapy. Osteoporos Int. 2013;24:1523–5.PubMedCrossRef
85.
Bjorgul K, Reigstad A. Atypical fracture of the ulna associated with alendronate use. Acta Orthop. 2011;82:761–3.PubMedCrossRef
86.
Bissonnette L, April PM, Dumais R, Boire G, Roux S. Atypical fracture of the tibial diaphysis associated with bisphosphonate therapy: a case report. Bone. 2013;56:406–9.PubMedCrossRef
87.
Imbuldeniya AM, Jiwa N, Murphy JP. Bilateral atypical insufficiency fractures of the proximal tibia and a unilateral distal femoral fracture associated with long-term intravenous bisphosphonate therapy: a case report. J Med Case Rep. 2012;6:50.PubMedCentralPubMedCrossRef
Metadata
Title
Review: Epidemiology and Pathophysiology of Atypical Femur Fractures
Authors
Alvin C. Ng
Meng Ai Png
David T. Chua
Joyce S. B. Koh
Tet Sen Howe
Publication date
01-03-2014
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 1/2014
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-014-0198-z

Other articles of this Issue 1/2014

Current Osteoporosis Reports 1/2014 Go to the issue

Skeletal Biology and Regulation (MR Forwood and A Robling, Section Editors)

Osteoblast-Chondrocyte Interactions in Osteoarthritis

Osteoimmunology (D Novack and G Schett, Section Editors)

Impact of Inflammation on the Osteoblast in Rheumatic Diseases

Osteoimmunology (D Novack and G Schett, Section Editors)

Bone and the Innate Immune System

Regenerative Biology and Medicine in Osteoporosis (EM Schwartz and RE Guldberg, Section Editors)

Local Strategies to Prevent and Treat Osteoporosis

Epidemiology and Pathophysiology (PR Ebeling and EF Eriksen, Section Editors)

Vitamin D Deficiency and its Role in Muscle-Bone Interactions in the Elderly

Osteoimmunology (D Novack and G Schett, Section Editors)

Mesenchymal Progenitors and the Osteoblast Lineage in Bone Marrow Hematopoietic Niches